Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232583 · ClinicalTrials.gov registry record · NA
Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
A NA study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 58
- Enrollment target
NCT00232583: Completed NA study, sponsored by University of Texas Southwestern Medical Center.
NCT00232583 is a NA study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 58 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00232583, a NA study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
Study Summary
The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.
Primary Outcome
C-peptide AUC during a 3-hours mixed meal challenge testing
Interventions
- DRUG Metformin
- DRUG Pioglitazone
- DRUG Insulin
- DRUG glyburide
- DRUG Metfomin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2003-11 |
| Est. Completion | 2011-12 |
| Phase | NA |
What the finished NCT00232583 record still lists
NCT00232583 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT00232583 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00232583 about?
NCT00232583 is a clinical study titled "Preservation of Beta-cell Function in Type 2 Diabetes Mellitus". The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.
What is the current status of trial NCT00232583?
This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2003-11. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00232583?
The interventions under investigation include: Metformin (DRUG), Pioglitazone (DRUG), Insulin (DRUG), glyburide (DRUG), Metfomin (DRUG).
Who is sponsoring clinical trial NCT00232583?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00232583's enrollment target sits among peer trials
58 1256th of 2000 higher than 740 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia